^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Regimen: | CaRD (carfilzomib + dexamethasone injection + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: PRIMARY THERAPY FOR WM/LPL...Other Recommended Regimens…Carfilzomib/rituximab/dexamethasone
